From: Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study
COVID-19 drug pair
ADR
Atazanavir–hydroxychloroquine
55 (25.3%)
Lopinavir/ritonavir–hydroxychloroquine
34 (15.7%)
Lopinavir/ritonavir–interferon beta-1b
5 (2.3%)
Atazanavir–favipiravir
1 (0.5%)
Lopinavir/ritonavir–chloroquine